Recently released market study: Stada Arzneimittel Generics Company Intelligence Report

Feb. 13, 2011 - PRLog -- Stada Arzneimittel is one of the two major independent German generic manufacturers, along with ratiopharm. However, with Teva's recently-announced acquisition of ratiopharm, Stada will soon be the only major independent generic manufacturer in Germany.

Sales in 2005 broke the one billion euro barrier for the first time; in 2008, sales reached 1,646.2 million euros, but dipped in 2009 to 1,568.8 million euros (US$2,187.9 million). However, net income rose by 31.8% to 100.4 million euros (US$140.0 million).

Unbranded generics accounted for around 71.2% of sales, with the bulk of the remainder being branded generic products. Stada operates two core segments: Generics and Branded Products.

Stada is a Euro-centric firm. Sales in Europe accounted 1,501.0 million euros (US$2,093.3 million) or around 96% of Stada's sales in 2009, with sales in Germany accounting for around 34%.

The USA is not an important market for Stada at the moment. In July 2006, the company announced the sale of its US business to DAVA, effectively exiting the market.

Stada is working on a number of biosimilar products, through an agreement with Bioceuticals Arzneimittel AG

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/121464_stada_arzneimittel_gene...


Report Table of Contents:

Executive Summary
Introduction
Build the future
Products
Stada Arzneimittel: top five API sales in 2009, in euro millions and US$ millions
Stada Arzneimittel: number of product launches per year
Biosimilars
Financial results
Latest Interim Results, First Nine Months of 2010
Stada Arzneimittel: nine month results, in euro 000s and US$000s
Stada Arzneimittel: quarterly results, in euro 000s
Stada Arzneimittel: quarterly results, in US$000s
Stada Arzneimittel: selected regional nine month results, in euro 000s and US$000s
Stada Arzneimittel: selected regional quarterly results, in euro 000s
Stada Arzneimittel: selected regional quarterly results, in US$000s
Latest Fiscal Year Results, FY09
Stada Arzneimittel: fiscal year results, in euro millions
Stada Arzneimittel: fiscal year results, in US$ millions
Segment Data
Stada Arzneimittel: fiscal year results by segment, in euro millions
Stada Arzneimittel: fiscal year results by segment in US$ millions
Geographic Segment Data
Germany
Russia
Belgium
Serbia
Italy
France
Spain
United Kingdom
Stada Arzneimittel: selected geographic segment data, in euros millions
Stada Arzneimittel: selected geographic segment data, in US$ millions
Major developments
Litigation
Stada says olanzapine judgement will cost the firm
Contact Details

About Espicom Business Intelligence

Espicom Business Intelligence is a highly-regarded and established provider of business intelligence services. Founded in 1982 as MDIS Publications Ltd, the company changed its name to Espicom in 1992. Initially a publisher in a wide range of industries such as power generation and telecommunications, they now focus on the global pharmaceutical and medical device sectors.  View more research from Espicom Business Intelligence at http://www.fastmr.com/catalog/publishers.aspx?pubid=1025

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.